Summary.-The present studies in mice and cancer-bearing patients, treated with C. parvum (CP) immunotherapy, were to determine the effects of CP on the production of immune complexes (IC) and associated disease.
IMMUNE-COMPLEX DISEASE IN MICE AND HUMANS
Summary.-The present studies in mice and cancer-bearing patients, treated with C. parvum (CP) immunotherapy, were to determine the effects of CP on the production of immune complexes (IC) and associated disease. Using the Clq -binding assay, circulating immune complexes were detected in mice given a single high dose of CP (466 ,ug) and repeated human-equivalent doses (70 ,ug) .
All mice treated with CP developed proliferative glomerulonephritis, the severity of which was dose-related. The histological and immunofluorescent patterns of the nephritis were those attributed to immune-complex disease. The mice had haematuria but were not in renal failure. Fifty patients with inoperable lung cancer were studied. All received radiotherapy. Twenty-two had no other treatment (controls) and 28 were treated with infusions of CP. Using 2 immune-complex assays (Clq binding and monoclonal rheumatoidfactor binding) IC were found in 10/22 control patients but these did not develop haematuria or proteinuria. Twenty-four of the 28 patients treated with CP developed transient haematuria and/or proteinuria with red -cell and hyaline casts, the changes resolving over 5 days. Immune complexes were detected in 5 of these 28 patients before CP treatment. Although 16/28 had IC at the time of haematuria and proteinuria, these findings were difficult to interpret because IC may occur in response to the tumour, the radiotherapy, or the CP. Although no patient developed renal failure, we believe that those treated with CP should have regular assessment of their renal function.
CORYNEBACTERIUM PARVUM (CP) is an immunopotentiating agent (Halpern et al., 1953; Howard et al., 1973) which inhibits the growth of a variety of animal tumours (Halpern et al., 1966; Smith & Scott, 1972; Sadler & Castro, 1976) . It has been used to treat patients with malignant disease (Israel, 1975; Takita & Moayeri, 1976; Sarna et al., 1977 Samples of blood and urine were taken immediately before and 2 days after each CP infusion. Control patients were seen every 2 months.
CP antibody. Antibodies to CP were measured by passive agglutination. Doubling dilutions of serum were made with phosphatebuffered saline to a total volume of 50 ,u in each well of microtitre plate. 25 jul of a 0 7 mg/ml CP suspension was added to each well. The mixtures were incubated for 2 h at 37°C and then at 4°C for 48 h. Agglutination was observed and the antibody titres expressed as pow-ers of 2.
Urine analysis.-Urine was examined for blood and protein using Multistix (Ames). Specimens were centrifuged and the deposits examined bv light microscopy.
ITt1wlmmune-conmplex assay,s
Clq-binding (ClqB). This assay was performed as previously described (Pussell et al., 1978) . Purified radiolabelled Clq was incubated with test sera in the presence of ethylenediaminetetra-acetate (EDTA). Free and bound Clq were then separated by precipitation with polyethylene glycol (mol. wt 6000). The amount of radioactivity in the precipitate was taken to represent the amount of immune complexes. Results were expressed as the percentage of total protein-bound radioactivity. In human sera, levels > 2-70; were considered abnormal (Pussell et al., 1978) .
The same assay using Clq wNas used to test mouse sera. Normal untreated mice had a mean level of 16 6 + 10-.0%. Levels exceeding 30% were considered abnormal.
Monoclonal rheumatoid factor (niRF). Purified monoclonal IgM rheumatoid factor was radiolabelled and used in a similar assay to the ClqB assay (Barratt & Naish, 1979 (Fig. 2) . Those receiving a single high dose had moderate mesangial proliferation, which was more diffuse but with some segmental accentuation. Occasional crescents were present. Tubules and interstitium were unaffected. At 6 and 9 weeks the changes were similar, but there was scarring and less proliferation. Kidneys from mice receiving repeated low doses examined at 6 weeks showed marked diffuse mesangial proliferation in their glomeruli, with frequent crescents (Fig. 3) . There was some necrosis but few polymorphs and the capillary loops did not appear thickened. The tubules and interstitium were normal. Three weeks later there appeared to be some recovery, as there were fewer crescents, mesangial proliferation was slightly reduced and the mesangial matrix was increased.
Immnunofiuorescence. Kidneys from control mice did not stain for complement. Some control mice had small amounts of granular mesangial staining for immunoglobulin. By 1 week those animals that received a single dose (low or high) showed moderate granular mesangial staining for both immunoglobulin and complement (Fig. 4) . At 9 weeks immunoglobulin staining had returned to the levels seen in control animals, but mild complement staining persisted.
By 6 weeks mice receiving repeated low doses showed mild granular mesangial staining for immunoglobulin, and considerable granular mesangial staining for complement. At 9 weeks there was virtually no staining for immunoglobulin but considerable complement staining persisted. Granular deposits were seen in the capillary loops as well as in the mesangium.
Cancer patients
Twenty-eight patients treated with CP received a total of 63 infusions. Eight completed the planned course of infusions and 3 others continue in the programme. Seventeen failed to complete the programme; 5 withdrew with disease progression to a pre-terminal phase and 12 considered the side-effects of the treatment unacceptable (fever, malaise and rigors) and refused further infusions. Twenty-two control patients were seen on a total of 43 occasions. titre (power of 2) in (P-treated patients rose progressively with each infusion, reaching a median level of 13 (range 10-16) after 4 infusions. Control patients had a median titre of 7 (range 6-11).
Urine analysis and serumt urea and creatinine concentrations.-Twenty-four of the CP-treated patients had haematuria and/or proteinuria after CP infusion. In some patients haematuria occurred only once, but in 5 it was found after every infusion. Haematuria and proteinuria developed 1 day after treatment, were great,est on the 2nd or 3rd day, and had resolved by the 4th or 5th day. Haematuria was confirmed by the presence of red blood cells. Red-cell and hyaline casts were seen. None of the control patients had haematuria or proteinuria. All patients had normal urea and creatinine concentrations and CP treatment did not affect these.
Immnune complex. Immune-complex measurements showed good correlation between the ClqB assay and the mRFA (r=0-89, n=150). ICs were detected before treatment in 5 CP patients. No significant acute change in Clq binding was detected when pre-and post-CP treatment values were compared, and there was no difference between patients with, and those without, haematuria and proteinuria. However, over the 4 months, there was a gradual rise in Clq binding, so that IC were detected in 17 patients after CP. In 16 these were associated with haematuria and proteinuria. IC was detected in 6 of the control patients before treatment and in 10 4 months after starting radiotherapy.
Rheumatoid factor. Rheumatoid factor was detected in the serum of 5 CP patients and 5 controls. These patients, excepting 1 CP and I control, had IC. (Levinsky & Soothill, 1979) .
We have not attempted to identify the antigen responsible for the IC disease induced in mice by CP. It is possible that the antigen is CP itself, or that the powerful adjuvant action of CP (Sljivic & Watson, 1977) may stimulate a response to another unknown antigen.
In conclusion, mice treated with CP developed proliferative glomerulonephritis due to immune-complex deposition. Thev had haematuria but not renal failure. Patients with lung cancer treated with CP often developed haematuria and proteinuria. Immune complexes may occur in these patients in response to the tumour, to radiotherapy or to CP. Although none of our patients developed renal failure, we agree with Dosik et al. (1978) that those treated with CP should have regular assessment of their renal function.
